{"id":6310,"date":"2025-02-18T16:26:09","date_gmt":"2025-02-18T16:26:09","guid":{"rendered":"https:\/\/healthnews.zone\/?p=6310"},"modified":"2025-02-18T16:26:10","modified_gmt":"2025-02-18T16:26:10","slug":"breakthrough-mrna-across-the-blood-brain-barrier-could-treat-alzheimers-and-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/healthnews.zone\/?p=6310","title":{"rendered":"Breakthrough: mRNA Across the Blood-Brain Barrier Could Treat Alzheimer\u2019s and Parkinson\u2019s Disease"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">For decades, scientists have faced a major challenge in treating brain disorders: how to get therapeutic drugs past the blood-brain barrier (BBB). The BBB is a natural defense system that protects the brain from harmful substances, but it also prevents most medications from reaching brain cells. This has made it extremely difficult to develop effective treatments for neurological diseases such as Alzheimer\u2019s and Parkinson\u2019s disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Now, researchers at the Icahn School of Medicine at Mount Sinai have developed a cutting-edge technology that could change the future of brain treatments. They have designed a new type of lipid nanoparticle\u2014called blood-brain-barrier-crossing lipid nanoparticles (BLNPs)\u2014that can successfully deliver messenger RNA (mRNA) into the brain through an intravenous injection. This breakthrough, published in <em>Nature Materials<\/em>, could open the door to revolutionary treatments for a wide range of conditions, including neurodegenerative diseases, brain cancer, and psychiatric disorders.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The Blood-Brain Barrier: A Major Obstacle in Brain Treatment<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The blood-brain barrier is a highly selective filter that protects the brain from infections and toxins. It consists of tightly packed cells that line the blood vessels in the brain, preventing large molecules\u2014including most drugs\u2014from entering. While this system is essential for brain health, it has also made it incredibly difficult to develop effective treatments for brain diseases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scientists have tried various approaches to bypass the BBB, such as injecting drugs directly into the brain or using ultrasound to temporarily open the barrier. However, these methods can be risky and impractical for widespread use. This is why researchers have long been searching for a way to safely and efficiently transport therapeutic molecules into the brain without invasive procedures.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">A New Solution: Lipid Nanoparticles for mRNA Delivery<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The team at Mount Sinai has created a new type of lipid nanoparticle capable of carrying mRNA across the BBB. These nanoparticles take advantage of natural transport mechanisms in the barrier, including caveolae- and \u03b3-secretase-mediated transcytosis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;Our study shows that these blood-brain barrier-crossing lipid nanoparticles (BLNPs) can safely and efficiently deliver mRNA into the brain,&#8221; says Dr. Yizhou Dong, a senior author of the study and professor at the Icahn School of Medicine at Mount Sinai. &#8220;This could open up opportunities to use mRNA-based therapies for a variety of neurological and psychiatric disorders.&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The researchers tested different lipid formulations to find the best design for crossing the BBB. Through detailed analysis, they identified a leading formulation, MK16 BLNP, which showed significantly better mRNA delivery efficiency than existing FDA-approved lipid nanoparticles. When injected into mice, the BLNP system successfully delivered mRNA to brain cells, proving its potential for real-world use.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How This Could Help Patients<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The ability to deliver mRNA to the brain could lead to groundbreaking treatments for a wide range of neurological disorders. Some of the key conditions that could benefit from this technology include:<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Neurodegenerative Diseases<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Alzheimer\u2019s Disease<\/strong> \u2013 mRNA therapies could help clear amyloid-beta plaques, reduce tau protein tangles, and slow cognitive decline.<\/li>\n\n\n\n<li><strong>Parkinson\u2019s Disease<\/strong> \u2013 mRNA could restore dopamine-producing neurons, which are lost in Parkinson\u2019s, potentially improving motor function and slowing disease progression.<\/li>\n\n\n\n<li><strong>Huntington\u2019s Disease<\/strong> \u2013 mRNA-based interventions might help reduce toxic protein buildup and slow disease progression.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Neuromuscular and Genetic Disorders<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Amyotrophic Lateral Sclerosis (ALS)<\/strong> \u2013 mRNA therapy could help deliver crucial genes to slow nerve degeneration and improve motor function.<\/li>\n\n\n\n<li><strong>Spinal Muscular Atrophy (SMA)<\/strong> \u2013 mRNA encoding SMN1 protein could help prevent motor neuron loss and extend mobility in patients.<\/li>\n\n\n\n<li><strong>Friedreich\u2019s Ataxia<\/strong> \u2013 mRNA treatments might restore missing mitochondrial proteins to improve energy production and neurological function.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Brain Cancer<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Glioblastoma and Other Brain Tumors<\/strong> \u2013 mRNA-based immunotherapy could trigger the immune system to attack tumors or directly deliver tumor-suppressing genes.<\/li>\n\n\n\n<li><strong>Medulloblastoma<\/strong> \u2013 Targeted mRNA treatments could help inhibit tumor growth or make tumors more sensitive to chemotherapy.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Neuroinflammatory and Autoimmune Diseases<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Multiple Sclerosis (MS)<\/strong> \u2013 mRNA therapy could help repair damaged myelin, the protective covering of nerves, or regulate immune system activity to slow the disease.<\/li>\n\n\n\n<li><strong>Lupus-related Neuroinflammation<\/strong> \u2013 mRNA-based interventions might prevent autoimmune attacks on the brain and reduce inflammation.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Stroke and Traumatic Brain Injury (TBI)<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ischemic Stroke<\/strong> \u2013 mRNA treatments could help brain cells survive, promote recovery, and restore lost function after a stroke.<\/li>\n\n\n\n<li><strong>TBI and Concussions<\/strong> \u2013 mRNA encoding neurotrophic factors could help regenerate damaged neurons and reduce inflammation.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Psychiatric and Cognitive Disorders (Emerging Research)<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Schizophrenia and Bipolar Disorder<\/strong> \u2013 mRNA therapies could help regulate neurotransmitter imbalances associated with these conditions.<\/li>\n\n\n\n<li><strong>Autism Spectrum Disorder (ASD)<\/strong> \u2013 Targeted mRNA treatments might help correct genetic mutations linked to ASD and improve brain connectivity.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">What Comes Next?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">While this breakthrough is promising, researchers emphasize that more studies are needed to confirm the long-term safety and effectiveness of this approach. Future work will focus on refining the nanoparticle formulations, conducting toxicology studies, and advancing the technology toward human clinical trials.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;Our lipid nanoparticle system represents an important step in the effort to develop mRNA-based treatments for central nervous system disorders,&#8221; says Dr. Dong. &#8220;The study provides proof of concept that such an approach is viable and could be adapted for a range of diseases where gene therapy or mRNA therapeutics might play a role.&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dr. Eric J. Nestler, co-corresponding author and Director of The Friedman Brain Institute, adds, &#8220;Our findings highlight the potential of lipid nanoparticles in overcoming one of the major challenges in treating brain diseases. We are very excited to continue evaluating this novel platform for broader therapeutic applications.&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With further research and development, this technology could soon lead to groundbreaking treatments, offering hope to millions of people suffering from neurological disorders.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>For decades, scientists have faced a major challenge in treating brain disorders: how to get therapeutic drugs past the blood-brain barrier (BBB). The BBB is a natural defense system that protects the brain from harmful substances, but it also prevents most medications from reaching brain cells. This has made it extremely difficult to develop effective treatments for neurological diseases such as Alzheimer\u2019s and Parkinson\u2019s disease. Now, researchers at the Icahn School of Medicine at Mount Sinai have developed a cutting-edge [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":6311,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":["post-6310","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mental-health"],"_links":{"self":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/6310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6310"}],"version-history":[{"count":2,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/6310\/revisions"}],"predecessor-version":[{"id":6313,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/6310\/revisions\/6313"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/media\/6311"}],"wp:attachment":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}